Private Wealth Asset Management LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 89.1% in the third quarter, Holdings Channel reports. The firm owned 21,212 shares of the company’s stock after buying an additional 9,997 shares during the period. Eli Lilly and Company comprises about 1.3% of Private Wealth Asset Management LLC’s portfolio, making the stock its 12th largest position. Private Wealth Asset Management LLC’s holdings in Eli Lilly and Company were worth $24,544,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in shares of Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares during the last quarter. State Street Corp grew its position in Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after purchasing an additional 605,752 shares during the last quarter. Bank of America Corp DE purchased a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Eli Lilly and Company by 1.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock valued at $8,647,153,000 after purchasing an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC increased its stake in Eli Lilly and Company by 7.9% during the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock valued at $6,550,587,000 after purchasing an additional 400,538 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on LLY shares. Citigroup lifted their price objective on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Bank of America reissued a “buy” rating and issued a $1,497.00 price objective on shares of Eli Lilly and Company in a report on Friday, October 30th. Royal Bank Of Canada restated an “outperform” rating and issued a $1,600.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday. UBS Group lifted their target price on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Finally, Jefferies Financial Group upped their target price on Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the company a “buy” rating in a research report on Monday, November 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $1,422.00.
Get Our Latest Report on Eli Lilly and Company
Key Headlines Impacting Eli Lilly and Company
Investors following LLY have been watching these headlines:
- Positive Sentiment: Health Canada approved Mounjaro (tirzepatide) to reduce major cardiovascular risks in adults with type 2 diabetes and established cardiovascular disease, expanding the medicine’s potential use. Health Canada approves Lilly’s Mounjaro to reduce cardiovascular risk
- Positive Sentiment: Some Wall Street commentary remains bullish: Jefferies reportedly has the highest price target among analysts, and Barclays recently raised its target while maintaining an Overweight rating. Jefferies has Wall Street’s highest target on Eli Lilly
- Negative Sentiment: A report that Lilly stopped highlighting dose counts prompted questions about what the change signals for demand and disclosure, adding uncertainty around its obesity-drug growth story. Separately, State Street’s health-care ETF sold $42.3 million of Lilly shares, a potential source of near-term selling pressure. Eli Lilly stopped touting dose counts. Should you worry?
Eli Lilly and Company Trading Down 2.2%
NYSE LLY opened at $1,352.18 on Friday. The company has a market capitalization of $1.27 trillion, a PE ratio of 43.89, a P/E/G ratio of 1.65 and a beta of 0.40. The company has a fifty day moving average of $1,263.45 and a 200 day moving average of $1,117.53. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,475.25. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. During the same period last year, the business earned $7.02 earnings per share. Eli Lilly and Company’s quarterly revenue was up 38.6% on a year-over-year basis. Research analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current year.
Eli Lilly and Company Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s payout ratio is 22.46%.
Insiders Place Their Bets
In other news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the sale, the executive vice president directly owned 4,137 shares of the company’s stock, valued at $5,802,225.24. This represents a 54.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
